Pulmonx Corporation
NASDAQ:LUNGMedical - Devices
+$0.05 today
- Market cap
- $117.15M
- Beta
- 0.28
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$1.27
Volume 0.48M
Average 0.44M
LUNG Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Pulmonx CorporationNASDAQ: LUNG
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $2.03M rose 205.1% year over year, ahead of the +92.8% change in trailing-twelve-month financing cash flow. Sequentially, it rose 3583.6% from the prior quarter. Over 3 fiscal years it compounded at -28.5% a year.
Context
- Financing cash flow amounted to 1.0% of revenue in FY2025, down 0.6 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +205.1% holds above the trailing-twelve-month pace of +92.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 903K USD
- Year-over-year change
- -33.7%
- 4-year CAGR
- -33.1%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 903K | -33.7% |
| FY2024 | 2024-12-31 | 1.36M | -93.6% |
| FY2023 | 2023-12-31 | 21.4M | +765.7% |
| FY2022 | 2022-12-31 | 2.47M | -45.0% |
| FY2021 | 2021-12-31 | 4.5M | — |
Financing Cash Flow vs competitors
How LUNG compares with its peers on the latest reported figures
- LUNG's LTM Mar 2026 financing cash flow of $2.24M is the 6th largest of the 10 companies compared; the peer median is $4.07M.
- Its year-over-year change of +92.8% is the 4th highest of 10, against a peer median of +4.7%.
- Financing cash flow amounts to 2.5% of revenue for LUNG, versus a peer median of 2.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $254.22M | +330054.5% | -11.9% | — | |
| LTM Mar 2026 | $250.14M | +95540.9% | +27.6% | — | |
| LTM Mar 2026 | $36.41M | +456.2% | +1477.9% | 237.5% | |
| LTM Jun 2026 | $25.56M | -40.4% | -14.3% | 32.0% | |
| LTM Mar 2026 | $4.07M | -89.4% | -37.6% | 1.6% | |
| LTM Mar 2026 | $2.24M | +92.8% | -28.5% | 2.5% | |
| LTM Mar 2026 | $495K | +53.3% | -19.2% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $439K | -100.4% | — | — |
| LTM Mar 2026 | $267K | +4.7% | -71.1% | 0.3% | |
| LTM Mar 2026 | $189K | -99.9% | — | 2.1% | |
| Peer median (excluding LUNG) | $4.07M | +4.7% | -14.3% | 2.1% | |
Competitors are the stored peer set for LUNG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (48.66M) | (58.92M) | (60.84M) | (56.39M) | (54M) |
| Depreciation & Amortization | 3.16M | 4M | 1.55M | 1.49M | 1.15M |
| Deferred Income Tax | (6K) | 49K | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 22.1M | 22.96M | 0 |
| Change in Working Capital | (7.84M) | (7.06M) | (2.56M) | (1.7M) | (1.93M) |
| Accounts Receivables | (2.43M) | (2.19M) | (3.1M) | (1.31M) | 1.08M |
| Inventory | (6.46M) | (3.64M) | 918K | (229K) | (765K) |
| Accounts Payables | 87K | 247K | (345K) | 2.28M | 270K |
| Other Working Capital | 963K | (1.48M) | (27K) | (2.44M) | (2.51M) |
| Other Non-Cash Items | 11.92M | 16.8M | 2.14M | 2.11M | 22.33M |
| Operating Cash Flow | (41.43M) | (45.14M) | (37.61M) | (31.54M) | (32.45M) |
| Capital Expenditures | (3.67M) | (1.32M) | (807K) | (1.45M) | (452K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (52.58M) | (47.19M) | (46.2M) | (27.91M) | (5.65M) |
| Sales of Investments | 10M | 44.28M | 45M | 46.84M | 36.59M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (46.26M) | (4.23M) | (2.01M) | 17.48M | 30.48M |
| Debt Repayment | 0 | (87K) | 19.91M | (95K) | (100K) |
| Common Stock Issued | 4.52M | 2.59M | 0 | 0 | 1M |
| Common Stock Repurchased | (26K) | (27K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 1.49M | 1.46M | 0 |
| Financing Cash Flow | 4.5M | 2.47M | 21.4M | 1.36M | 903K |
| Effect of Forex Changes | 106K | 145K | 34K | 76K | (92K) |
| Net Change in Cash | (83.08M) | (46.74M) | (18.18M) | (12.62M) | (1.15M) |
| Free Cash Flow | (45.1M) | (46.45M) | (38.42M) | (32.98M) | (32.9M) |
Pulmonx Corporation
NASDAQ:LUNG
Intrinsic Alpha fair value
Locked
Current Price
$2.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.